858 results about "Blood specimen" patented technology

The invention discloses a blood, urine and body fluid collecting, detecting, analyzing and uploading system based on multi-sensor integration, which comprises the following modules: a blood collecting module for collecting a blood sample; the urine collection module is used for detecting urine; the body fluid collecting module is used for detecting body fluid; the data processing module is used for preprocessing data; the feature extraction and classification module is used for constructing a multi-modal feature matrix based on a neural structure search network, a support vector machine and a random forest algorithm; the anomaly detection module is used for generating a weighted anomaly score in combination with an isolated forest and a depth anomaly detection model; the time sequence analysis module is used for analyzing the health trend by using a variational auto-encoder-generative adversarial network; the health portrait and risk assessment module is used for constructing a health map by adopting a graph convolutional network; and the encryption and uploading management module is used for encrypting by using AES and RSA and managing the data access authority based on the intelligent contract. According to the invention, a multi-modal sensor and an intelligent algorithm are integrated, and collection, detection, analysis, encryption and uploading of blood, urine and body fluid are realized.

The invention provides an individualized management system and method for colorectal cancer risk prediction, and relates to the technical field of medical diagnosis and individualized medical treatment. The system comprises a multi-omics data processing module used for collecting a blood sample of a subject, extracting circulating free DNA, and sequencing cfDNA by adopting a simplified methylation sequencing technology to obtain final original data of DNA methylation characteristics; the risk prediction module is used for carrying out bioinformatics analysis on the original data of the final DNA methylation features by adopting a machine learning algorithm, extracting a methylation feature set, a tail end motif feature set and a breakpoint motif feature set, and carrying out risk prediction on the basis of the extracted feature sets; and predicting the colorectal cancer disease risk of the subject by using a pre-trained prediction model to obtain a prediction result. The problem that the risk prediction accuracy of the colorectal cancer is low is solved.

The invention discloses a sugar chain marker combination for predicting prognosis of liver cancer transarterial chemoembolization and application of the sugar chain marker combination. The invention discovers and verifies that the combination composed of NA3Fb, NA4Fb and NA4F2b can be used as a novel marker for evaluating TACE treatment reaction and prognosis by analyzing a serum sugar chain map of a liver cancer patient for the first time. Based on the marker combination, a TACE-GT prognosis scoring model and system are established, and the progression risk of a patient within 12 months after a TACE operation can be effectively distinguished by noninvasively detecting the expression levels of three carbohydrate chains in serum of the patient and calculating a specific score. The detection method provided by the invention is based on a blood sample, and has the advantages of noninvasiveness and convenience, and a risk assessment system can provide individualized curative effect prediction and decision support for clinicians before and after TACE treatment, and has important values for realizing precise treatment of liver cancer and improving prognosis of patients.

The invention relates to the technical field of cancer risk prediction, in particular to a deep learning cancer risk prediction method and system based on a methylation sequence. The method comprises the following steps: acquiring DNA methylation sequencing data and reference genome annotation data in a blood sample of a cancer patient; performing functional region classification processing on the DNA methylation sequencing data according to the reference genome annotation data to obtain promoter subregion methylation data, enhancement subregion methylation data and transcription factor binding site methylation data; performing dynamic sequence similarity calculation processing on the methylation data of the promoter region to obtain a first feature vector containing importance weight of the promoter region of the cancer-related gene; the methylation sites are classified according to the functions of the methylation sites in the transcriptional regulation pathway, so that the biological interpretation of the characteristics is improved, and the synergistic effect among different functional regions can be captured.

The invention discloses a multichannel blood sample shunt detection glucometer, and belongs to the technical field of glucometers, the multichannel blood sample shunt detection glucometer comprises a base, the top side in the base is fixedly connected with a protective cover, the bottom side in the protective cover is provided with a detection disc, and the bottom side in the detection disc is provided with a mounting groove. According to the device, a driving motor drives a detection disc, a connecting shaft and a gear to rotate, the gear drives the connecting shaft, an annular block and an arc-shaped convex block to rotate under the action of a fan-shaped fluted disc, and the arc-shaped convex block can extrude a roller, a connecting rod and a second spring in the rotating process; a plurality of rollers intermittently drive a connecting rod, a spherical hinge support and a spherical hinge support to move upwards, that is, a fixed seat continuously drives a blood sample storage transparent tube to perform shaking, vibration and static settlement treatment, so that blood and a reagent in the blood sample storage transparent tube are fully mixed and reacted; therefore, the subsequent blood glucose detection precision of the equipment on the blood in the blood sample storage transparent tube is ensured.

Provided is a method for estimating a factor causing an abnormality in coagulation of a blood sample. In the method, 1) a parameter Ps relating to a coagulation reaction in a sample S and a parameter Pm relating to a coagulation reaction in a sample M are calculated, 2) an estimation as to whether the sample S is coagulation-factor-inhibitor-positive is carried out on the basis of Ps, and 3) a sample S that is not estimated to be coagulation-factor-inhibitor-positive in 2) is estimated to be lupus-anticoagulant-positive or coagulation-factor-deficient on the basis of Pm or on the basis of Ps and Pm. The sample S is a test blood sample having an extended coagulation time, the sample M is a mixed sample of the sample S and a sample N, and the sample N is a normal blood sample. Ps is calculated on the basis of a measurement point or time at which a coagulation reaction curve or a coagulation speed curve of the sample S reaches a prescribed value, and Pm is calculated on the basis of a measurement point or time at which a coagulation reaction curve or a coagulation speed curve of the sample M reaches a prescribed value.

The invention belongs to the technical field of medical detection, and discloses a blood disease high-throughput detection method based on a micro-fluidic chip and SERS (Surface Enhanced Raman Scattering) detection, which comprises the following steps: introducing a blood sample into the micro-fluidic chip with a micro-fluidic channel; the method comprises the following steps: performing SERS (Surface Enhanced Raman Scattering) detection on a blood sample through a nano-structure surface preset in a micro-fluidic channel; according to the present invention, with the microfluidic chip and the SERS technology, the high-throughput detection of the blood sample is achieved, the SERS spectrum data is collected and analyzed, the disease marker in the blood is identified, and the high-throughput detection of the blood sample is achieved through the combination of the microfluidic chip and the SERS technology. A plurality of micro-channels on the micro-fluidic chip can process a plurality of samples in parallel, the detection efficiency is remarkably improved, and the strength of Raman scattering signals can be remarkably improved by utilizing the surface enhancement effect of the SERS technology, so that high-sensitivity detection of blood disease markers is realized, and the detection cost is reduced. Accurate control and efficient separation of trace samples are achieved through the micro-fluidic chip, complex pretreatment steps are not needed, and the operation process is simplified.

The invention provides a dilution buffer solution for chemiluminescence detection of a blood sample. The dilution buffer solution contains 0.05 to 1 weight percent of plasmin and 0.005 to 0.02 weight percent of a de-foaming agent. The dilution buffer solution provided by the invention can reduce the jump value phenomenon in chemiluminescence detection of a blood sample, especially a repeatedly frozen and thawed blood sample, so that a correct and reliable detection result is provided for clinic, and the clinical detection time can be saved.

The application presently discloses a method of treating atherosclerosis in a human subject comprising administering an effective amount of an IL-8 inhibitor, an IL-6 inhibitor, and / or an IL-1β inhibitor, wherein the subject has a TET2 and / or DNMT3A mutation thereby treating atherosclerosis. It also discloses a method for treating atherosclerosis in a human subject comprising sequencing at least a part of a genome comprising TET2 and / or DNMT3A of one or more cells in a blood sample of the subject; determining from the sequencing whether the subject has one or more mutations in TET2 and / or DNMT3A, if it is determined that the subject has at least one TET2 and / or DNMT3A mutation, administering an IL-8 inhibitor, an IL-6 inhibitor, and / or an IL-1β inhibitor to a subject to the subject thereby treating atherosclerosis.

In some embodiments, a method for classifying elements of a blood sample is provided, the method including: digitally staining an image of the blood sample using a trained machine learning model to generate a digitally stained image; extracting one or more intermediate features generated by the trained machine learning model during the digital staining of the image; providing the one or more extracted intermediate features to a trained multi-class classifier; and employing the trained multi-class classifier to classify at least one element in the blood sample based on the one or more extracted intermediate features. Many other embodiments are also provided.

Analyzers and methods of use are disclosed, including a blood analyzer comprising a light source to transmit an optical signal; a detector to generate data indicative of optical signal intensity; a transparent sample vessel between the light source and the detector; a dispensing device to pass a first portion of the blood sample comprising whole blood or lysed blood into the vessel at a first instance of time, and to pass a plasma portion of the blood sample into the vessel at a second instance of time; a controller to cause a processor to obtain first and second data generated by the detector, the first data indicative of the optical signal passing through the first portion of the blood sample and the second data indicative of the optical signal passing through the plasma, to determine a total absorbance spectrum in which the first data is adjusted by the second data.

A blood cell analyzer (100) and a blood cell analysis method (300). The blood cell analysis method (300) comprises: sucking a blood sample to be tested; preparing a first determination sample and obtaining first optical information; preparing a second determination sample and obtaining second optical information; generating a first leukocyte classification scatter diagram and a second leukocyte classification scatter diagram; determining a first counting result of neutrophils of the to-be-detected blood sample based on the first leukocyte classification scatter diagram and the second leukocyte classification scatter diagram; determining an actual distribution area of neutrophils from the first leukocyte classification scatter diagram; based on a reference distribution region of neutrophils of a reference leukocyte classification scatter diagram of the normal blood sample, determining a leaf-division nucleophore distribution region from the actual distribution region; determining a second counting result of the cells falling into the leaf-separating nucleogranulocyte distribution area; and based on the first counting result and the second counting result, determining a counting result of the rod-shaped nuclear granulocytes in the to-be-detected blood sample.

The invention relates to the technical field of cardiovascular disease detection, and discloses a blood ceramide and cardiovascular event correlation analysis system, a data acquisition module is used for acquiring a plurality of blood samples of different groups of patients, acquiring blood ceramide data by using a mass spectrometry detection method, and collecting clinical index data corresponding to the patients; the data processing module is used for cleaning the acquired blood ceramide data and clinical index data, removing abnormal values and missing values, and performing standardization processing on the data to obtain processed data; the feature extraction module is used for extracting target feature data associated with the cardiovascular event from the processed data; the correlation analysis module is used for inputting the target characteristic data into a blood ceramide and cardiovascular event correlation analysis model, predicting the risk of the cardiovascular event through the correlation analysis model, formulating a personalized prevention and treatment scheme and outputting a correlation analysis result; the present invention is helpful to reveal complex relationships between blood ceramides and cardiovascular events.

The invention discloses a prediction marker and a prediction method for acute upper respiratory infection susceptibility. The prediction marker and the prediction method are used for solving the problem that current acute upper respiratory infection susceptibility risk prediction is low in accuracy. The method comprises the following steps: firstly, providing a prediction marker for acute upper respiratory infection susceptibility, wherein the prediction marker is a prediction feature combination obtained by comprehensively considering human health state blood routine data and baseline blood transcriptome data and carrying out feature processing; secondly, providing a prediction method, and obtaining a to-be-detected blood sample; and performing blood analysis based on a to-be-detected blood sample, inputting the obtained blood routine sample and the gene expression sample into a susceptibility prediction model pre-trained based on a prediction marker for susceptibility risk judgment, and obtaining a susceptibility risk assessment result of acute upper respiratory infection of a human body corresponding to the to-be-detected blood sample in a future period of time, therefore, the acute upper respiratory infection susceptibility risk of the human body in a period of time in the future can be simply, quickly and accurately predicted.

The invention belongs to the technical field of biomedicine, and particularly relates to application of ceramide as a marker in prediction of hepatocellular carcinoma microvascular invasion risk. The invention finds that the preoperative plasma ceramide CER (d18: 1 / 16: 0) level can be used for predicting the MVI of HBV-HCC patients and evaluating the postoperative prognosis of the patients for the first time. The invention provides a preoperative non-invasive detection method based on plasma ceramide CER (d18: 1 / 16: 0), and trauma of traditional histopathology detection is avoided. According to the method, the occurrence risk of the MVI can be effectively reduced by simply detecting a blood sample of a patient. According to the method, the MVI risk of a patient is evaluated through a multi-factor prediction model, and a basis is provided for personalized treatment. The method is not only suitable for preoperative MVI risk assessment, but also can assist in making postoperative follow-up visit and treatment plans, and helps to reduce the postoperative recurrence rate and improve the survival rate of patients.

Provided are a method for diagnosing cancer, a diagnosis kit and compositions useful for measurement of NK cell activity. The incidence of cancer may be diagnosed by monitoring changes in the in vivo immune system through measurement of NK cell activity in blood. Thus, the incidence of cancer may be readily predicted as described herein using a blood sample from a subject.

The invention relates to the field of drug concentration detection, in particular to a rapid tacrolimus drug concentration detection device based on a micro-fluidic chip. The detection device comprises a blood sampling area, a separation area, a liquid medicine storage area, a waste liquid storage area and a spectrograph, the separation area is used for separating a tacrolimus medicine in a blood sample solution, and a liquid medicine sample and a waste liquid sample are obtained; the spectrograph is used for collecting liquid medicine spectral data of the liquid medicine sample in the liquid medicine storage area and waste liquid spectral data of the waste liquid sample in the waste liquid storage area, and detecting the concentration of the tacrolimus medicine in the blood sample solution according to the liquid medicine spectral data and the waste liquid spectral data. According to the invention, the accuracy of detecting the concentration of the tacrolimus drug in the blood can be improved.

The utility model discloses a tip blood taking needle capable of automatically collecting a blood sample, and particularly relates to the field of tip blood sampling, the tip blood taking needle comprises a device main body, and the middle part of the surface of one side of the device main body is fixedly connected with a connecting end; the needle body is connected to the middle of the connecting end in an embedded mode, and the needle head is fixedly connected to the other side of the needle body. When the blood sampling device is used, the connecting end of the device body is firmly connected with a needle body to ensure that the blood sampling process is stable, the needle cap protects the needle head and prevents pollution, the connector is connected with a blood sampling tube to facilitate collection of blood samples, the nested threaded shaft facilitates fixation of the blood sampling tube, and the embedded cavity, the piston disc, the elastic rod, the pressing rod and the like form a blood sampling power system. The piston disc can be driven to move through easy operation of the pressing rod, blood sampling is automatically completed, the friction force between the device body and the palm of a user is enhanced through the non-slip mat, the use safety is improved, the whole device is compact in design and easy and convenient to operate, and the blood sampling efficiency and safety are greatly improved.

This invention discloses a blood purification device and medical system. The blood purification device includes: a device housing; a blood purifier; a blood tubing assembly, the blood tubing assembly including a first blood tubing connecting a human blood vessel to the inlet of the blood purifier and a second blood tubing connecting the outlet of the blood purifier to the human blood vessel; a power assembly including a blood pump for driving blood flow within the blood tubing assembly, a first replenishment pump for allowing anticoagulant solution to flow into the first blood tubing, and / or a second replenishment pump for allowing calcium solution to flow into the second blood tubing; and a blood component analysis component disposed within the device housing, the blood component analysis component being used to detect collected blood samples. This design facilitates the appropriate adjustment of anticoagulant drugs and calcium ions in the blood purification circuit.

The present invention provides a kit and a detection method for synchronously detecting catecholamines and their metabolites, which relates to the technical field of analytical detection. The kit contains a diluent, a solid-phase extraction reagent, an LC-MS / MS detection reagent, a solid-phase extraction device, and a solid-phase extraction packing material. Among them, the solid-phase extraction packing material creatively adopts zwitterionic exchange microspheres containing both carboxyl and quaternary ammonium groups. The kit can not only synchronously and efficiently separate and detect 8 kinds of catecholamines and their metabolites in urine samples, but also separate and detect 6 kinds of amino-containing catecholamines and their metabolites in blood samples. When the above kit is used to separate and detect catecholamines and their metabolites, the extraction recovery rate is relatively high, and the linear range covers the reference value range of normal detection, which can significantly shorten the detection time of urine samples, improve the detection efficiency of mass spectrometry, and is conducive to popularization and application in clinical detection.

The invention discloses a blood coagulation analyzer which is characterized in that a reagent adding assembly is used for adding a reagent into a reaction cup at least containing a blood sample; the incubation assembly comprises a plurality of incubation bins and heaters arranged corresponding to the incubation bins, the incubation bins are used for placing reaction cups containing blood samples and reagents, and the heaters are used for heating the reaction cups to execute incubation actions; the first detection assembly and the second detection assembly respectively comprise a plurality of detection positions and optical detection elements, and the optical detection elements detect detection signals for analysis from the detection samples placed on the detection positions based on detection requirements of corresponding detection methodology; the transferring assembly is used for transferring the reaction cups at least partially placed in the incubation bin to a detection position; and a processor for analyzing the blood sample based on the detection signal. By adopting the blood coagulation analyzer, the problems that the blood coagulation analyzer is complex in structure and low in detection efficiency, and the channel difference exists between different fixed detection positions are solved.

The invention discloses an active tuberculosis diagnostic marker, a kit and application thereof. In particular to application of a reagent for detecting a diagnostic marker in preparation of a kit for diagnosing active tuberculosis, the diagnostic marker is a biomarker TRIM22 in a blood sample, and the sequence of the TRIM22 is as shown in SEQ ID NO: 1. According to the invention, TRIM22 in a blood sample is used as a biomarker for detecting active tuberculosis for the first time. Results of ROC curve analysis show that the expression level of TRIM22 in whole blood has good sensitivity and specificity for active tuberculosis diagnosis. Therefore, the invention overcomes the defects of low detection rate, long time consumption and the like of the existing active tuberculosis diagnosis, has the characteristics of good specificity and high sensitivity, and has good clinical application value for the auxiliary diagnosis of the active tuberculosis.

This disclosure describes methods of and systems for screening for sepsis or septic shock in a patient and methods of ruling out sepsis or septic shock in a patient using white blood cell count (WBC), a monocyte cell population parameter, or neutrophil-to-lymphocyte ratio (NLR), or a combination thereof, in the blood sample from the patient.

The invention discloses a method for identifying Yushan black pigs by adopting an SNP (Single Nucleotide Polymorphism) molecular marker technology, and particularly relates to the technical field of molecular detection.The method comprises the following steps: S1, sample preparation: collecting any one of ear tissues, tail tips or blood samples of to-be-detected pig individuals, and extracting to obtain genome DNA (Deoxyribose Nucleic Acid); the genome DNA is used as a template, amplification detection is conducted through a first primer pair, a second primer pair, a third primer pair and a fourth primer pair corresponding to the first SNP site, the second SNP site and the fourth SNP site, and the nucleotide sequences of the first primer pair, the second primer pair and the fourth primer pair are sequentially SEQ ID NO.5-SEQ ID NO.12. By detecting the specific single nucleotide polymorphic sites in the Yushan black pig genome and carrying out genetic typing comparison, the Yushan black pigs and the filial generation thereof can be quickly and accurately identified.

The invention belongs to the field of medical examination equipment, and provides a medical examination sampling device and a use method.The medical examination sampling device comprises a sampling table, a fixed baffle is fixedly installed on the edge of the upper surface of the sampling table, an operation window is formed in the bottom of one end of the fixed baffle, and a fixed groove is formed in the middle of the top end of the sampling table; the conveying mechanism comprises supporting rollers, the supporting rollers are symmetrically and rotationally installed on the two side edges of the inner wall of the fixing groove, the outer surfaces of the supporting rollers are sleeved with a conveying belt, a stepping motor is installed in the middle of one end of each supporting roller, positioning assemblies are arranged on the outer surface of the conveying belt at certain intervals, and limiting clamping pipes are installed on the portions, in the positioning assemblies, of the outer surface of the conveying belt. By means of the automatic separating and collecting structure (the connecting rotary disc, the fixing clamping sleeve and the collecting box), non-contact recycling of blood sampling parts is achieved, direct contact between medical workers and blood samples and sharp tools is reduced, and occupational exposure risks are remarkably reduced.

A microfluidic device (12) for applying blood samples to a sensor element (26) for protein defect diagnosis and / or for conditioning a sensor element (26) for protein defect diagnosis is proposed, as is a protein defect diagnosis device (10) with the microfluidic device (12). A method for applying blood samples to a sensor element (26) for protein defect diagnosis and / or for conditioning a sensor element (26) for protein defect diagnosis and a method for analyzing protein defects in a blood sample (212) are also disclosed.

A sample analysis system (10), comprising a sample storage apparatus (100), a sample measurement apparatus (200), a sample container transfer apparatus (300), a first photographic apparatus (400) and a control apparatus (500). The control apparatus (500) is configured to obtain a first target image on the basis of an image captured by means of the first photographic apparatus (400) executing a first photographing action, and to output at least one of the following pieces of information: the first target image, a determination result for indicating whether there are clots in an intermediate layer liquid (32), and a determination result for indicating the degree of coagulation in a blood sample (30), wherein the first target image at least includes an image showing an interface liquid surface (321) or an interface liquid layer in a two-dimensional form and / or a three-dimensional form for use as a basis for determining whether there are clots in the intermediate layer liquid (32) and / or as a basis for determining the degree of coagulation in the blood sample (30). The probability of missed detection of early coagulation in the blood sample (30) is reduced, and the accuracy of determining whether clots have formed in the blood sample (30) before aspiration is improved.

The invention relates to the technical field of infectious disease detection, and discloses a new respiratory infectious disease early warning method, which comprises the following steps: S1, specimen collection and data collection: collecting biological samples of new respiratory infectious disease virus infected individuals and other respiratory infectious disease virus infected individuals, the biological sample comprises a blood sample and a swab sample; meanwhile, basic information of the individuals is collected, wherein the basic information comprises gender, age and respiratory symptom duration; s2, quantitative detection: the biological sample is subjected to quantitative detection by adopting reagents of various respiratory infectious disease viruses, the detection content comprises antigens and antibodies, and the antibodies comprise an I gM antibody, an I gG antibody and an I gA antibody; according to the invention, basic information of individuals and antigen-antibody detection reagent resources of various respiratory infectious disease viruses are deeply integrated, so that the recognition capability of new respiratory infectious disease virus infected individuals is effectively improved.

The invention discloses a gastric cancer biomarker composition as well as a screening method and application thereof, and belongs to the technical field of bioinformatics. The screening method of the gastric cancer biomarker composition comprises the following steps: firstly, collecting blood specimens of a gastric cancer patient and a healthy control, carrying out high-throughput plasma proteomics detection, and screening out differential expression proteins; and verifying the candidate protein markers by using a prospective queue in the British biological sample library, and finally determining 17 core proteins to obtain the gastric cancer biomarker composition. A gastric cancer risk prediction model is constructed by combining clinical risk factors and protein expression levels of gastric cancer biomarkers. The gastric cancer risk prediction model constructed by the invention can realize accurate layering of gastric cancer risks, decision curve analysis shows that the net benefit of the model is obviously superior to that of a traditional screening method, and an efficient tool is provided for early warning and personalized intervention of gastric cancer.